The Treatment of Irritable Bowel Syndrome with Hypnotherapy
Overview
Authors
Affiliations
Previous research from the United Kingdom has shown hypnotherapy to be effective in the treatment of irritable bowel syndrome (IBS). The current study provides a systematic replication of this work in the United States. Six matched pairs of IBS patients were randomly assigned to either a gut-directed hypnotherapy (n = 6) or to a symptom monitoring wait-list control condition (n = 6) in a multiple baseline across subjects design. Those assigned to the control condition were later crossed over to the treatment condition. Subjects were matched on concurrent psychiatric diagnoses, susceptibility to hypnosis, and various demographic features. On a composite measure of primary IBS symptoms, treatment was superior (p = .016) to symptom monitoring. Results from the entire treated sample (n = 11; one subject was removed from analysis) indicate that the individual symptoms of abdominal pain, constipation, and flatulence improved significantly. State and trait anxiety scores were also seen to decrease significantly. Results at the 2-month follow-up point indicated good maintenance of treatment gains. No significant correlation was found between initial susceptibility to hypnosis and treatment gain. A positive relationship was found between the incidence of psychiatric diagnosis and overall level of improvement.
Amsallem F, Sanchez S, Armoiry X, Mion F Evid Based Complement Alternat Med. 2021; 2021:4404185.
PMID: 34790245 PMC: 8592737. DOI: 10.1155/2021/4404185.
Best management of irritable bowel syndrome.
Black C, Ford A Frontline Gastroenterol. 2021; 12(4):303-315.
PMID: 34249316 PMC: 8231425. DOI: 10.1136/flgastro-2019-101298.
Psychotherapeutic Interventions in Irritable Bowel Syndrome.
Hetterich L, Stengel A Front Psychiatry. 2020; 11:286.
PMID: 32425821 PMC: 7205029. DOI: 10.3389/fpsyt.2020.00286.
Werner K, Arditte Hall K, Griffin M, Galovski T J Clin Sleep Med. 2019; 15(9):1329-1336.
PMID: 31538604 PMC: 6760408. DOI: 10.5664/jcsm.7930.
Vasant D, Whorwell P Neurogastroenterol Motil. 2019; 31(8):e13573.
PMID: 30815936 PMC: 6850508. DOI: 10.1111/nmo.13573.